The latest price target for Avalo Therapeutics (NASDAQ:AVTX) was reported by Citizens on April 6, 2026. The analyst firm set a price target for $52.00 expecting AVTX to rise to within 12 months (a possible 192.96% upside). 10 analyst firms have reported ratings in the last year.

The latest analyst rating for Avalo Therapeutics (NASDAQ:AVTX) was provided by Citizens, and Avalo Therapeutics initiated their market outperform rating.

The last upgrade for Avalo Therapeutics Inc happened on April 16, 2024 when Oppenheimer raised their price target to $35. Oppenheimer previously had a perform for Avalo Therapeutics Inc.

The last downgrade for Avalo Therapeutics Inc happened on June 27, 2023 when Oppenheimer changed their price target from N/A to N/A for Avalo Therapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Avalo Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Avalo Therapeutics was filed on April 6, 2026 so you should expect the next rating to be made available sometime around April 6, 2027.

While ratings are subjective and will change, the latest Avalo Therapeutics (AVTX) rating was a initiated with a price target of $0.00 to $52.00. The current price Avalo Therapeutics (AVTX) is trading at is $17.75, which is within the analyst’s predicted range.